KPMG – Artificial intelligence and biopharma

This  report highlights the current use of artificial intelligence (AI) in the biopharma industry, particularly in research and development. However, there are still opportunities for increased integration of AI in downstream commercial operations. The paper discusses the use of generative AI, such as large language models like OpenAI's ChatGPT, to enhance the drug discovery process and improve operations. The paper also explores key trends in the biopharma industry that demonstrate the enduring impact of AI. It focuses on the investment strategies and adoption of AI by the top 10 biopharmaceutical companies to enhance their existing capabilities and pipeline activities. The expanding landscape of biopharma company models, with an emphasis on AI-focused entities in the pharmaceutical and service spaces, is also evaluated. The objective of this paper is to provide insights into the factors influencing the acceptance and integration of AI-driven paradigms in the wider biopharma community. The analysis supports the hypothesis that AI-driven biopharma manufacturers and service companies will play a crucial role in the industry in the years to come.